Anixa Biosciences, Inc.

NasdaqCM:ANIX Voorraadrapport

Marktkapitalisatie: US$94.2m

Anixa Biosciences Beheer

Beheer criteriumcontroles 3/4

De CEO Anixa Biosciences is Amit Kumar, benoemd in Jul2017, heeft een ambtstermijn van 8.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.55M, bestaande uit 32% salaris en 68% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.85% van de aandelen van het bedrijf, ter waarde $ 1.75M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.9 jaar en 7.7 jaar.

Belangrijke informatie

Amit Kumar

Algemeen directeur

US$2.5m

Totale compensatie

Percentage CEO-salaris32.01%
Dienstverband CEO8.9yrs
Eigendom CEO1.9%
Management gemiddelde ambtstermijn8.9yrs
Gemiddelde ambtstermijn bestuur7.7yrs

Recente managementupdates

Recent updates

Analyseartikel • Mar 25

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Dec 19

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 40%?

Key Insights The projected fair value for Anixa Biosciences is US$4.21 based on 2 Stage Free Cash Flow to Equity Anixa...
Analyseartikel • Sep 12

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analyseartikel • May 23

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analyseartikel • Jan 19

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analyseartikel • Oct 06

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analyseartikel • Apr 27

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Key Insights The projected fair value for Anixa Biosciences is US$7.24 based on 2 Stage Free Cash Flow to Equity Anixa...
Analyseartikel • Jan 13

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Anixa Biosciences...
Analyseartikel • Sep 26

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 15

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

The shares of clinical-stage biotech Anixa Biosciences (NASDAQ:ANIX) jumped ~11% to reach the highest level since November on the announcement that the first patient received its chimeric antigen receptor T-cell (CAR-T) therapy in a Phase 1 clinical trial for ovarian cancer.   The dose escalation study conducted with its partner Moffitt Cancer Center is designed to assess the early efficacy data, safety and maximum tolerated dose of the follicle-stimulating hormone receptor T-cells. The trial is expected to enroll up to 48 patients at the Moffitt Cancer Center. Anixa’s (ANIX) CAR-T approach used in the study is known as chimeric endocrine receptor T-cell (CER-T) therapy. It differs from traditional CAR-T drugs in that it specifically targets the follicle-stimulating hormone receptor (FSHR) which, according to research, is exclusively located in ovarian cells of healthy adult women. In March, Anixa (ANIX) announced initial plans to conduct the trial.
Seeking Alpha • Jul 21

Anixa to get additional US patent linked to breast cancer vaccine technology

Anixa Biosciences (NASDAQ:ANIX) said the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to the company's breast cancer vaccine technology. The company said the technology has been exclusively licensed from and is being developed in partnership with Cleveland Clinic. The patent is titled 'Breast Cancer Vaccine' and the lead inventor is Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. "This breast cancer vaccine has the potential to prevent Triple Negative Breast Cancer ("TNBC"), the deadliest form of breast cancer, and perhaps other forms of breast cancer that express alpha-lactalbumin," said Anixa Chairman and CEO Amit Kumar.
Analyseartikel • Jun 13

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • May 11

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably. Trial enrollment for the vaccine trial was fast, and the company seems optimistic about the near-term future of the company. The market is huge, and if the trial is successful, chances are we are seeing the beginning of a huge spike in share price. 2022 will, in any case, be the year for Anixa, with other programs ongoing as well.
Analyseartikel • Feb 24

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Oct 28

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Anixa Biosciences...
Seeking Alpha • Sep 23

Our First Look At Anixa Biosciences

Today, we take an in-depth look at Anixa Biosciences, a small developmental firm on the west coast. The company's pipeline has multiple 'shots on goal' including one candidate that has shown some early analytical potential promise against the Covid-19 Delta variant. A full analysis is provided in the paragraphs below.
Analyseartikel • Jun 12

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analyseartikel • Jan 13

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyse CEO-vergoeding

Hoe is Amit Kumar's beloning veranderd ten opzichte van Anixa Biosciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Apr 30 2026n/an/a

-US$10m

Jan 31 2026n/an/a

-US$10m

Oct 31 2025US$3mUS$815k

-US$11m

Jul 31 2025n/an/a

-US$11m

Apr 30 2025n/an/a

-US$12m

Jan 31 2025n/an/a

-US$12m

Oct 31 2024US$3mUS$785k

-US$13m

Jul 31 2024n/an/a

-US$12m

Apr 30 2024n/an/a

-US$12m

Jan 31 2024n/an/a

-US$11m

Oct 31 2023US$4mUS$720k

-US$10m

Jul 31 2023n/an/a

-US$11m

Apr 30 2023n/an/a

-US$11m

Jan 31 2023n/an/a

-US$12m

Oct 31 2022US$2mUS$631k

-US$14m

Jul 31 2022n/an/a

-US$14m

Apr 30 2022n/an/a

-US$16m

Jan 31 2022n/an/a

-US$15m

Oct 31 2021US$11mUS$573k

-US$13m

Jul 31 2021n/an/a

-US$11m

Apr 30 2021n/an/a

-US$9m

Jan 31 2021n/an/a

-US$10m

Oct 31 2020US$2mUS$522k

-US$10m

Jul 31 2020n/an/a

-US$10m

Apr 30 2020n/an/a

-US$9m

Jan 31 2020n/an/a

-US$9m

Oct 31 2019US$665kUS$476k

-US$12m

Compensatie versus markt: De totale vergoeding ($USD 2.55M ) Amit } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 637.50K ).

Compensatie versus inkomsten: De vergoeding van Amit is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Amit Kumar (62 yo)

8.9yrs
Tenure
US$2,546,684
Compensatie

Dr. Amit Kumar, Ph.D. was a Director at Ascent Solar Technologies, Inc. since June 2007 until September 16, 2022 and had been its Independent Chairman of the Board since January 2011 until September 16, 20...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Amit Kumar
CEO, Chairman & Co-Chair of CBAB8.9yrsUS$2.55m1.85%
$ 1.7m
Michael Catelani
President9.6yrsUS$1.30m0.13%
$ 123.3k
Pamela Garzone
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board4.8yrsgeen gegevensgeen gegevens
8.9yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van ANIX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.9 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Amit Kumar
CEO, Chairman & Co-Chair of CBAB13.6yrsUS$2.55m1.85%
$ 1.7m
Pamela Garzone
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board3.3yrsgeen gegevensgeen gegevens
Lewis Titterton
Lead Independent Director8.9yrsUS$134.63k2.86%
$ 2.7m
H. Shepard
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Linda Kelley
Member of Scientific Advisory Board7.7yrsgeen gegevensgeen gegevens
Ian Frazer
Member of Scientific Advisory Board6.7yrsgeen gegevensgeen gegevens
G. Budd
Member of Breast Cancer Clinical Advisory Board3.3yrsgeen gegevensgeen gegevens
Arnold Baskies
Member of SAB & Breast Cancer Clinical Advisory Board7.8yrsUS$134.63k0.40%
$ 374.0k
Marco Davila
Member of Scientific Advisory Board7.7yrsgeen gegevensgeen gegevens
Jose Conejo-Garcia
Member of Scientific Advisory Board7.7yrsgeen gegevensgeen gegevens
Daniel Abate-Daga
Member of Scientific Advisory Board7.7yrsgeen gegevensgeen gegevens
Emily Gottschalk
Independent Director6.7yrsUS$134.63k0.13%
$ 126.5k
7.7yrs
Gemiddelde duur
73yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ANIX wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.7 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/06/23 23:30
Aandelenkoers aan het einde van de dag2026/06/23 00:00
Inkomsten2026/04/30
Jaarlijkse inkomsten2025/10/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Anixa Biosciences, Inc. wordt gevolgd door 6 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Andrew D'SilvaB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.
Ilya ZubkovFreedom Broker